AbbVie, Calibr partner to develop T-cell therapies for solid tumors

This article was originally published here

Biopharmaceutical firm AbbVie and Calibr, the drug discovery division of Scripps Research, have entered into a collaboration to develop T-cell therapies aimed mainly at cancer, including solid tumors.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply